SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. / Sarafidis, Pantelis; Ferro, Charles J.; Morales, Enrique; Ortiz, Alberto; Malyszko, Jolanta; Hojs, Radovan; Khazim, Khaled; Ekart, Robert; Valdivielso, Jose; Fouque, Denis; London, Gérard M.; Massy, Ziad; Ruggenenti, Petro; Porrini, Esteban; Wiecek, Andrej; Zoccali, Carmine; Mallamaci, Francesca; Hornum, Mads.
I: Nephrology Dialysis Transplantation, Bind 34, Nr. 2, 2019, s. 208-230.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
AU - Sarafidis, Pantelis
AU - Ferro, Charles J.
AU - Morales, Enrique
AU - Ortiz, Alberto
AU - Malyszko, Jolanta
AU - Hojs, Radovan
AU - Khazim, Khaled
AU - Ekart, Robert
AU - Valdivielso, Jose
AU - Fouque, Denis
AU - London, Gérard M.
AU - Massy, Ziad
AU - Ruggenenti, Petro
AU - Porrini, Esteban
AU - Wiecek, Andrej
AU - Zoccali, Carmine
AU - Mallamaci, Francesca
AU - Hornum, Mads
PY - 2019
Y1 - 2019
N2 - Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium-glucose cotransporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.
AB - Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium-glucose cotransporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.
KW - Albuminuria
KW - Diabetic kidney disease
KW - GLP-1 receptor agonists
KW - Proteinuria
KW - SGLT-2 inhibitors
U2 - 10.1093/ndt/gfy407
DO - 10.1093/ndt/gfy407
M3 - Journal article
C2 - 30753708
AN - SCOPUS:85061507462
VL - 34
SP - 208
EP - 230
JO - Nephrology, Dialysis, Transplantation
JF - Nephrology, Dialysis, Transplantation
SN - 0931-0509
IS - 2
ER -
ID: 241367882